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“S
HARING is caring” 
is a familiar saying 
and has a significant 
meaning: when we share 
something with another 
person, we are caring for 
him/her. 
We demonstrate our concern and 
interest in him/her by sharing. Sharing is 
not restricted to material items; we may 
also contribute intangible items such as 
spiritual thoughts, any type of concept, our 
learnings or even our experience.
Collaboration is a dynamic, 
transactional, and successful process by 
which individuals assist one another in 
accomplishing team and organisational 
goals. Thus, it involves various persons 
who emerge when their unique talents are 
necessary for leading others and addressing 
current workplace requirements. 
Personally, I collaborated with my 
colleague, Prof S for 10 years. However, he 
betrayed me by stealing money and data. 
He is similar to Covid-19. How?
Tedros Adhanom Ghebreyesus, Director-
General of the World Health Organisation 
(WHO), issued a strong warning. According 
to him, the world was “on the edge of 
a devastating moral failure.” Wealthy 
countries scooped up available Covid-19 
vaccines, leaving only a few for the rest of 
the world - a replay of the 2009 influenza 
outbreak. 
“The penalty of this failure will be borne 
by the world’s poorest people’s lives and 
livelihoods,” Tedros added. He was entirely 
accurate. Today, several rich nations 
vaccinate children as young as 12 years 
old, despite the fact that they are highly 
unlikely to have serious Covid-19, while 
poorer countries lack vaccinations for 
health care personnel.
Covid-19 vaccine and  
the devilish face of humanity
Almost 85 per cent of Covid-19 vaccine 
doses distributed thus far have been 
distributed to inhabitants of high- and 
upper-middle-income countries. The 
countries with the lowest gross domestic 
product per capita have only 0.3 per cent. 
Tedros reaffirmed his denunciation of 
“outrageous inequality” during his opening 
remarks at the World Health Assembly on 
May 24. By September, he continued, each 
nation should have vaccinated at least 10 
per cent of its people. 
Global inequalities in health are not 
new. Massive swaths of the globe remain 
without life-saving medicines such as 
monoclonal antibodies. Even at a cost of 
pennies, vaccines and medications do not 
reach millions of people in need. 
However, the Covid-19 crisis brought the 
discrepancies to the forefront in a new and 
severe way. While vaccine leaders such as 
Israel, the United Kingdom, and the United 
States regain normality, India’s health 
system is collapsing under the weight 
of rising case numbers - while the world 
continues to record over five million cases 
and over 80,000 deaths each week. 
Apart from the moral argument, there 
is a strong reason to pursue more equal 
vaccination distribution: No region of 
the world can feel secure if the pandemic 
persists elsewhere, posing the risk of 
reintroduction and perhaps producing 
more lethal virus strains.
Vaccine supply still a serious issue
In low-income countries, fewer than one 
per cent of all vaccinations have been 
administered and Covid-19 instances are 
increasing globally, with variants posing 
a serious threat to development. While 
worldwide demand for Covid-19 vaccines 
continues to outstrip available supply, 
sufficient doses are now accessible to serve 
the world’s most vulnerable individuals. 
Indeed, some high-income countries 
have vaccinated more than half their 
population and acquired enough ‘future’ 
doses from manufacturers to vaccinate 
their whole population multiple times. 
Dose sharing offers immediate and obvious 
advantages.
By speeding and expanding vaccination 
coverage globally, dose sharing can assist 
in containing the spread of Covid-19 and 
preventing the development of other 
variants. These changes have the potential 
to spread globally, even in countries with 
high vaccination rates. 
While dose sharing has little to no 
effect on the immunisation objectives 
of many high-income countries, it may 
help restore life-saving services in other 
low and middle-income countries. It 
enables governments to rapidly immunise 
frontline health care personnel. 
This protects not just them, but also 
the health services upon which society’s 
most vulnerable members rely. While 
vaccination supply continues to be a 
serious issue, the doses that are now 
available are concentrated in far too few 
hands. 
Dose sharing is a cost-effective way 
to handle an acute supply shortage. 
While this is a temporary solution to 
guarantee nations have access to Covid-19 
vaccinations, it is lifesaving for health care 
workers and vulnerable populations in 
low-income countries – and may avert the 
collapse of health systems.
Restricted supply of raw materials
COVAX was founded in April 2020 to avert 
precisely the catastrophe that is unfolding 
now. The organisation, which was co-led 
by the WHO, the Coalition for Epidemic 
Preparedness Innovations (CEPI), and 
Gavi, the Vaccine Alliance, sought to gather 
nations together to invest in various 
vaccine candidates, which it would then 
divide them equally among members. 
The 92 poorest nations would be 
financed by high-income countries, 
businesses, and philanthropic groups. 
Tedros made a bold request at the World 
Health Assembly for all manufacturers to 
provide any new medicine to COVAX prior 
to commercialisation or to devote 50 per 
cent of their doses to the facility.
Allowing other businesses to employ 
vaccine formulations developed - and 
sometimes aggressively protected - by 
a few might also boost production. 
AstraZeneca and Oxford licenced Serum 
to produce its vaccine and then supported 
the company in acquiring the technology 
necessary to make it in India, a process 
known as technology transfer. 
The pharmaceutical industry reacted 
angrily to the statements, arguing that 
sharing intellectual property would 
impede innovation. Inexperienced 
new vaccine manufacturers would also 
deplete the restricted supply of raw 
materials, according to Pfizer CEO Albert 
Bourla, jeopardising “everyone’s safety 
and security.” Stéphane Bancel, CEO of 
Moderna, claimed that patent waiver is the 
“wrong question,” since it would prevent 
other businesses from developing mRNA 
vaccines this year or next, during “the 
pandemic’s most critical period.” 
While Moderna has agreed to not 
enforce its own Covid-19–related 
intellectual property rights during the 
pandemic, producing the vaccine requires 
licencing arrangements with other patent 
holders.
Inequitable distribution
Liberating intellectual property may 
enable existing manufacturers to produce 
previously inaccessible vaccines. However, 
new manufacturing facilities will be 
necessary in the long term to fulfil the 
needs of the have-nots—not just during 
this pandemic, but also throughout future 
ones. 
Covid-19 mutations and declining 
immunity to the virus might result in an 
annual immunisation demand of several 
billion doses. And if a new disease arises, 
the world’s population may require billions 
of fresh vaccine doses. 
The inequitable distribution of 
Covid-19 vaccines illustrates the limits of a 
system in which manufacturing power is 
concentrated in a few places. Now, the bulk 
of Covid-19 vaccine doses are made in the 
US, China, India, and Europe - all of which 
have been pressed to prioritise vaccination 
of their own populations. “Once we’ve 
completed ours, we’ll present it to you.” 
That argument is quite plain and acts as the 
conversation’s subtext.
Almost two years into the pandemic, 
Covid-19 has thrown light on tremendously 
tough topics. Our wish is to vaccinate every 
individual on the planet. 
That has never been done before. You 
may argue that if we do this in three years, 
we would have accomplished something 
unprecedented in human history. But 
when one considers the devastation caused 
by Covid-19, that looks to be a very, very 
long time. 
To summarise, developed nations 
monopolised the market for Covid-19 
vaccines. There are four options for 
protecting the rest of the globe and 
ensuring a more equitable distribution of 
the Covid-19 vaccine: support for COVAX, 
expansion of vaccine manufacturing, 
information exchange, and expansion of 
production plants globally. I think that all 
lives are created equal and that nobody is 
secure until everyone is safe. — The Health
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